

**Client:** Chi Med  
**Source:** Dow Jones  
**Date:** 01 November 2012

---

## **DJ Hutchison China Meditech Initiated Phase I trial of Theliatinib**

DJ Hutchison China Meditech Initiated Phase I trial of Theliatinib

LONDON--Hutchison China Meditech Limited (HCM.LN), a seller of traditional Chinese medicine and healthcare products, said Thursday that Hutchison MediPharma Limited, its majority owned R&D company, initiated the first-in-human Phase I clinical trial of Theliatinib (HMPL-309).

**MAIN FACTS:**

- This is the fourth oncology compound from the internal discovery programmes of HMP to enter into clinical development in China.
- The liatinib is a novel, orally active small molecule inhibitor targeting the wild type epidermal growth factor receptor ("EGFR") or resistant EGFR tumours.
- The first patient was dosed on Oct. 30.
- Shares at 0815 GMT up 1%, at 450 pence, valuing the company at GBP234 million.

-Write to Mark Shapland at [mark.shapland@dowjones.com](mailto:mark.shapland@dowjones.com)

Subscribe to WSJ: <http://online.wsj.com?mod=djnwires>

(END) Dow Jones Newswires

November 01, 2012 04:17 ET (08:17 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.